Glaxosmithkline Pharmaceuticals Ltd

Glaxosmi. Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glaxosmithkline Pharmaceuticals Ltd

₹ 3,021 0.07%
23 May - close price
gsk-india.com BSE: 500660 NSE: GLAXO
About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Key Points

Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

Website BSE NSE
  • Market Cap ₹ 51,176 Cr.
  • Current Price ₹ 3,021
  • High / Low ₹ 3,148 / 1,921
  • Stock P/E 55.4
  • Book Value ₹ 115
  • Dividend Yield 1.39 %
  • ROCE 66.9 %
  • ROE 49.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 37.2%
  • Company has been maintaining a healthy dividend payout of 108%

Cons

  • Stock is trading at 26.2 times its book value
  • The company has delivered a poor sales growth of 3.06% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational

Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
810 745 917 802 787 762 957 805 930 815 1,011 949 974
634 596 660 574 618 618 668 587 673 584 689 658 641
Operating Profit 175 149 257 229 170 144 289 218 257 231 322 292 333
OPM % 22% 20% 28% 29% 22% 19% 30% 27% 28% 28% 32% 31% 34%
1,322 31 22 12 38 54 28 -135 32 36 39 35 41
Interest 0 1 0 0 1 0 0 0 1 0 0 0 1
Depreciation 15 16 16 16 17 16 18 17 18 16 17 19 15
Profit before tax 1,482 163 262 224 190 181 299 65 271 249 344 308 359
Tax % 18% 27% 26% 27% 30% 27% 27% 30% 28% 27% 27% 25% 27%
1,219 119 193 165 133 132 218 46 194 182 252 230 263
EPS in Rs 71.96 7.04 11.42 9.71 7.88 7.81 12.84 2.70 11.48 10.76 14.91 13.57 15.52
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 15m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
2,563 3,305 2,838 2,908 2,871 3,128 3,224 2,926 3,278 3,252 3,454 3,749
2,034 2,672 2,360 2,489 2,363 2,527 2,567 2,327 2,516 2,447 2,545 2,572
Operating Profit 528 633 478 420 508 601 657 598 762 804 909 1,177
OPM % 21% 19% 17% 14% 18% 19% 20% 20% 23% 25% 26% 31%
203 149 125 119 70 131 -262 9 1,401 103 -21 151
Interest 0 0 0 0 0 1 6 4 2 2 2 1
Depreciation 20 25 25 27 38 49 83 79 68 66 70 67
Profit before tax 711 756 578 511 540 683 306 525 2,093 839 816 1,260
Tax % 32% 37% 35% 34% 35% 35% 70% 32% 19% 27% 28% 26%
482 476 376 337 351 445 93 358 1,695 611 590 928
EPS in Rs 28.43 28.12 22.20 19.88 20.70 26.29 5.50 21.14 100.04 36.05 34.83 54.75
Dividend Payout % 88% 111% 113% 75% 85% 76% 727% 142% 90% 89% 92% 142%
Compounded Sales Growth
10 Years: 1%
5 Years: 3%
3 Years: 5%
TTM: 9%
Compounded Profit Growth
10 Years: 6%
5 Years: 36%
3 Years: -18%
TTM: 41%
Stock Price CAGR
10 Years: 7%
5 Years: 17%
3 Years: 26%
1 Year: 24%
Return on Equity
10 Years: 30%
5 Years: 45%
3 Years: 37%
Last Year: 50%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 85 85 85 85 85 169 169 169 169 169 169 169
Reserves 1,905 1,744 2,099 1,922 1,973 1,970 1,651 1,309 2,494 1,572 1,608 1,782
4 3 2 2 1 1 0 35 20 16 19 10
1,136 1,384 869 995 1,889 1,771 1,312 1,602 1,950 1,570 1,760 2,147
Total Liabilities 3,130 3,216 3,055 3,004 3,947 3,911 3,133 3,115 4,633 3,327 3,557 4,108
100 123 204 258 325 432 758 387 331 330 321 284
CWIP 62 115 268 605 923 1,003 120 13 30 20 14 14
Investments 10 0 6 0 0 0 0 0 366 518 813 1,118
2,958 2,977 2,577 2,140 2,700 2,477 2,255 2,715 3,907 2,458 2,408 2,692
Total Assets 3,130 3,216 3,055 3,004 3,947 3,911 3,133 3,115 4,633 3,327 3,557 4,108

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
281 338 139 234 473 409 490 578 811 484 582 1,290
189 180 499 301 -104 -153 -57 418 -406 808 9 -46
-494 -497 -638 -511 -307 -358 -428 -696 -524 -1,543 -562 -769
Net Cash Flow -24 21 -0 24 62 -102 6 300 -119 -251 29 475

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 14 11 16 21 19 14 11 27 23 22 23 28
Inventory Days 109 91 156 111 147 131 135 159 144 131 144 126
Days Payable 90 74 97 73 149 109 100 135 156 122 171 186
Cash Conversion Cycle 33 27 75 60 17 36 46 50 11 31 -4 -31
Working Capital Days -45 -48 26 7 -90 -72 -38 -37 -92 -55 -62 11
ROCE % 34% 42% 29% 22% 26% 31% 33% 38% 37% 36% 51% 67%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.16% 2.17% 2.28% 2.28% 2.41% 2.50% 2.93% 3.48% 4.02% 4.36% 4.50% 4.52%
10.65% 10.54% 10.29% 10.31% 10.25% 10.01% 8.64% 7.90% 7.51% 7.34% 7.30% 7.79%
0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
12.19% 12.29% 12.43% 12.43% 12.35% 12.48% 13.42% 13.62% 13.48% 13.30% 13.21% 12.69%
No. of Shareholders 1,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,885

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls